Product name:
DOTA-TOC (Acetate salt)
Precursor for radiometal-labelled DOTA-TOC
Targeting of the somatostatin receptors for imaging and therapy
Molecular weight:
1421.6 [g/mol]
Molecular formula:
C65H92N14O18S2
*Delivery time: On request
General Information
| Product No.: | 50200, 50201 |
| Product name: | DOTA-TOC (Acetate salt) |
| Synonyms: | DOTATOC, Edotreotide, DOTA(0)-Phe(1)-Tyr(3))octreotide |
| Sequence: | DOTA–D-Phe–Cys–Tyr–D-Trp–Lys–Thr–Cys–Thr(ol)(cyclo 2-7) |
| Molecular weight: | 1421.6 [g/mol] |
| Molecular formula: | C65H92N14O18S2 |
| CAS No.: | 204318-14-9 |
Product Description
Enantiomerically pure, chemical precursor for radiopharmaceutical preparations with [68Ga], [90Y], [177Lu] or [225Ac].
For use by qualified personnel only.
Quantity
Product No. 50200: 1000 µg net peptide (lyophilisate, acetate salt)
Product No. 50201: 50 µg net peptide (lyophilisate, acetate salt)
Packaging
Clear tubular glass vials type I (borosilicate, 2 mL) with lyophilisation stoppers and closed with aluminium caps.
Storage and Stability
Storage at -20°C (± 5°C). Protect from light.
A temperature increase up to +40°C over a period of ≤ 3 days does not affect the purity of the chemical precursor.
However, elevated temperature might lead to a change in the appearance of the lyophilisate.
Certificates
Certificate of Analysis
Certificate of Compliance
Manufactured in full compliance with current EU GMP requirements. Specifications according to Ph. Eur. 2902 “Chemical precursors for radiopharmaceutical preparations”.
Literature
[1] Akurathi, V. et al., cGMP Production of 68Ga-DOTATOC in various radio synthesizers for imaging NETs, J Nucl Med 2018, 59 (supplement 1), 405.
[2] Lapa, C. et al., Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI, Oncotarget 2016, 7(47), 77807–77814.
[3] Luna-Gutierrez, M. et al., Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses, Pharmaceutics 2023, 15(7), 1988.
[4] Zhi, Y. et al., Somatostatin Receptor–Directed PET/CT Can Differentiate Between Differetiate Subtypes of Head and Neck Paragangliomas, Clin Nucl Med 2023, 48(11), 923-927.
